Analyzing Vyome (NASDAQ:HIND) and TranS1 (OTCMKTS:BAXSQ)

TranS1 (OTCMKTS:BAXSQ) and Vyome (NASDAQ:HIND) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Earnings and Valuation

This table compares TranS1 and Vyome”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TranS1	N/A	N/A	N/A	N/A	N/A
Vyome	$8.01 million	2.52	-$7.13 million	($433.08)	-0.01

TranS1 has higher earnings, but lower revenue than Vyome.

Analyst Recommendations

This is a summary of recent recommendations for TranS1 and Vyome, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TranS1	0	0	0	0	0.00
Vyome	0	0	2	0	3.00

Vyome has a consensus target price of $15.00, indicating a potential upside of 172.23%. Given Vyome’s stronger consensus rating and higher probable upside, analysts clearly believe Vyome is more favorable than TranS1.

Profitability

This table compares TranS1 and Vyome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TranS1	N/A	N/A	N/A
Vyome	-69.71%	-216.95%	-69.42%

Insider & Institutional Ownership

22.1% of Vyome shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Vyome beats TranS1 on 6 of the 9 factors compared between the two stocks.

About TranS1

Baxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company’s other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient’s hip for use in fusion procedures.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.